keyword
https://read.qxmd.com/read/38423050/surrogate-endpoints-in-clinical-trials-of-p16-positive-squamous-cell-carcinoma-of-the-oropharynx-an-individual-patient-data-meta-analysis
#1
JOURNAL ARTICLE
Laila A Gharzai, Emily Morris, Krithika Suresh, Phuc Felix Nguyen-Tân, David I Rosenthal, Maura L Gillison, Paul M Harari, Adam S Garden, Shlomo Koyfman, Jimmy J Caudell, Christopher U Jones, Darrion L Mitchell, Greg Krempl, John A Ridge, Michael F Gensheimer, James A Bonner, Edith Filion, Neal E Dunlap, William A Stokes, Quynh-Thu Le, Pedro Torres-Saavedra, Michelle Mierzwa, Matthew J Schipper
BACKGROUND: The increased incidence of human papillomavirus (HPV)-related cancers has motivated efforts to optimise treatment for these patients with excellent prognosis. Validation of surrogates for overall survival could expedite the investigation of new therapies. We sought to evaluate candidate intermediate clinical endpoints in trials assessing definitive treatment of p16-positive oropharyngeal cancer with chemotherapy or radiotherapy. METHODS: We did a retrospective review of five multicentre, randomised trials (NRG/RTOG 9003, 0129, 0234, 0522, and 1016) that tested radiotherapy with or without chemotherapy in patients (aged ≥18 years) with p16-positive localised head or neck squamous-cell carcinomas...
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423049/use-of-radiotherapy-in-patients-with-oesophageal-stomach-colon-rectal-liver-pancreatic-lung-and-ovarian-cancer-an-international-cancer-benchmarking-partnership-icbp-population-based-study
#2
JOURNAL ARTICLE
Sean McPhail, Matthew E Barclay, Ruth Swann, Shane A Johnson, Riaz Alvi, Andriana Barisic, Oliver Bucher, Nicola Creighton, Cheryl A Denny, Ron A Dewar, David W Donnelly, Jeff J Dowden, Laura Downie, Norah Finn, Anna T Gavin, Steven Habbous, Dyfed W Huws, S Eshwar Kumar, Leon May, Carol A McClure, David S Morrison, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Sabuj Sarker, Lorraine Shack, Xiaoyi Tian, Robert Js Thomas, Haiyan Wang, Ryan R Woods, Hui You, Bin Zhang, Georgios Lyratzopoulos
BACKGROUND: There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation. METHODS: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria)...
March 2024: Lancet Oncology
https://read.qxmd.com/read/38423048/use-of-chemotherapy-in-patients-with-oesophageal-stomach-colon-rectal-liver-pancreatic-lung-and-ovarian-cancer-an-international-cancer-benchmarking-partnership-icbp-population-based-study
#3
JOURNAL ARTICLE
Sean McPhail, Matthew E Barclay, Shane A Johnson, Ruth Swann, Riaz Alvi, Andriana Barisic, Oliver Bucher, Nicola Creighton, Cheryl A Denny, Ron A Dewar, David W Donnelly, Jeff J Dowden, Laura Downie, Norah Finn, Anna T Gavin, Steven Habbous, Dyfed W Huws, Leon May, Carol A McClure, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Sabuj Sarker, Lorraine Shack, Xiaoyi Tian, Robert J S Thomas, Catherine S Thomson, Haiyan Wang, Ryan R Woods, Hui You, Georgios Lyratzopoulos
BACKGROUND: There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. METHODS: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria)...
March 2024: Lancet Oncology
https://read.qxmd.com/read/38012893/treatment-related-adverse-events-including-fatal-toxicities-in-patients-with-solid-tumours-receiving-neoadjuvant-and-adjuvant-immune-checkpoint-blockade-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#4
JOURNAL ARTICLE
Yu Fujiwara, Nobuyuki Horita, Elio Adib, Susu Zhou, Amin H Nassar, Zain Ul Abideen Asad, Alessio Cortellini, Abdul Rafeh Naqash
BACKGROUND: Incorporating immune checkpoint blockade into perioperative cancer therapy has improved clinical outcomes. However, the safety of immune checkpoint blockade needs better evaluation, given the chances of more prolonged disease-free survival. We aimed to assess how adding immune checkpoint blockade to perioperative therapy affects treatment-related adverse events. METHODS: For this systematic review and meta-analysis, we searched PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from database inception until Aug 8, 2023, for randomised controlled trials that assessed the addition of immune checkpoint blockade to neoadjuvant or adjuvant therapy for cancer, reported treatment-related deaths, and had a design in which the experimental group assessed immune checkpoint blockade in combination with the therapy used in the control group...
January 2024: Lancet Oncology
https://read.qxmd.com/read/37517410/treatment-related-mortality-in-children-with-cancer-in-low-income-and-middle-income-countries-a-systematic-review-and-meta-analysis
#5
JOURNAL ARTICLE
Bella S Ehrlich, Michael J McNeil, Linh T D Pham, Yichen Chen, Jocelyn Rivera, Carlos Acuna, Liz Sniderman, Firas M Sakaan, Alejandra Mendez Aceituno, Cesar A Villegas, Lisa M Force, Nancy S Bolous, Parima P Wiphatphumiprates, Jeremy S Slone, Angela K Carrillo, Srinithya R Gillipelli, Caitlyn Duffy, Anita V Arias, Meenakshi Devidas, Carlos Rodriguez-Galindo, Sheena Mukkada, Asya Agulnik
BACKGROUND: Approximately 90% of children with cancer live in low-income and middle-income countries (LMICs), where 5-year survival is lower than 20%. Treatment-related mortality in high-income countries is approximately 3-5%; however, in LMICs, treatment-related mortality has been reported in up to 45% of children with cancer. This study aimed to systematically explore the burden of treatment-related mortality in children with cancer in LMICs and to explore the association between country income level and treatment-related mortality...
July 27, 2023: Lancet Oncology
https://read.qxmd.com/read/37414011/which-patients-with-metastatic-hormone-sensitive-prostate-cancer-benefit-from-docetaxel-a-systematic-review-and-meta-analysis-of-individual-participant-data-from-randomised-trials
#6
JOURNAL ARTICLE
Claire L Vale, David J Fisher, Peter J Godolphin, Larysa H Rydzewska, Jean-Marie Boher, Sarah Burdett, Yu-Hui Chen, Noel W Clarke, Karim Fizazi, Gwenaelle Gravis, Nicholas D James, Glenn Liu, David Matheson, Laura Murphy, Robert E Oldroyd, Mahesh K B Parmar, Ewelina Rogozinska, Patrick Sfumato, Christopher J Sweeney, Matthew R Sydes, Bertrand Tombal, Ian R White, Jayne F Tierney
BACKGROUND: Adding docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about who benefits most. We therefore aimed to obtain up-to-date estimates of the overall effects of docetaxel and to assess whether these effects varied according to prespecified characteristics of the patients or their tumours. METHODS: The STOPCAP M1 collaboration conducted a systematic review and meta-analysis of individual participant data...
July 2023: Lancet Oncology
https://read.qxmd.com/read/37269842/role-of-chemotherapy-in-patients-with-nasopharynx-carcinoma-treated-with-radiotherapy-mac-npc-an-updated-individual-patient-data-network-meta-analysis
#7
JOURNAL ARTICLE
Claire Petit, Anne Lee, Jun Ma, Benjamin Lacas, Wai Tong Ng, Anthony T C Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Wen-Fei Li, Pei-Yu Huang, Terence Tan, Roger K C Ngan, Guopei Zhu, Hai-Qiang Mai, Edwin P Hui, George Fountzilas, Li Zhang, Alexandra Carmel, Dora L W Kwong, James Moon, Jean Bourhis, Anne Auperin, Jean-Pierre Pignon, Pierre Blanchard
BACKGROUND: The meta-analysis of chemotherapy for nasopharynx carcinoma (MAC-NPC) collaborative group previously showed that the addition of adjuvant chemotherapy to concomitant chemoradiotherapy had the highest survival benefit of the studied treatment regimens in nasopharyngeal carcinoma. Due to the publication of new trials on induction chemotherapy, we updated the network meta-analysis. METHODS: For this individual patient data network meta-analysis, trials of radiotherapy with or without chemotherapy in patients with non-metastatic nasopharyngeal carcinoma that completed accrual before Dec 31, 2016, were identified and updated individual patient data were obtained...
June 2023: Lancet Oncology
https://read.qxmd.com/read/37142371/abiraterone-acetate-plus-prednisolone-with-or-without-enzalutamide-for-patients-with-metastatic-prostate-cancer-starting-androgen-deprivation-therapy-final-results-from-two-randomised-phase-3-trials-of-the-stampede-platform-protocol
#8
JOURNAL ARTICLE
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D Brown, Yatin Jain, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James
BACKGROUND: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. METHODS: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland...
May 2023: Lancet Oncology
https://read.qxmd.com/read/37100545/digital-health-and-telehealth-in-cancer-care-a-scoping-review-of-reviews
#9
REVIEW
Kelly M Shaffer, Kea L Turner, Chelsea Siwik, Brian D Gonzalez, Rujula Upasani, Jillian V Glazer, Robert J Ferguson, Catherine Joshua, Carissa A Low
The COVID-19 pandemic necessitated remote cancer care delivery via the internet and telephone, rapidly accelerating an already growing care delivery model and associated research. This scoping review of reviews characterised the peer-reviewed literature reviews on digital health and telehealth interventions in cancer published from database inception up to May 1, 2022, from PubMed, Cumulated Index to Nursing and Allied Health Literature, PsycINFO, Cochrane Reviews, and Web of Science. Eligible reviews conducted a systematic literature search...
May 2023: The Lancet. Digital health
https://read.qxmd.com/read/36933562/prevalence-of-human-papillomavirus-dna-and-p16-ink4a-positivity-in-vulvar-cancer-and-vulvar-intraepithelial-neoplasia-a-systematic-review-and-meta-analysis
#10
JOURNAL ARTICLE
Zhuang Li, Penglin Liu, Ziying Wang, Zhaoyang Zhang, Zhongshao Chen, Ran Chu, Guiju Li, Qiuyue Han, Yong Zhao, Li Li, Jinwei Miao, Beihua Kong, Kun Song
BACKGROUND: Human papillomavirus (HPV) DNA and p16INK4a positivity have crucial roles in the pathogenesis of vulvar cancer and vulvar intraepithelial neoplasia. We aimed to examine the pooled prevalence of HPV DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia worldwide. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, and the Cochrane Library databases for studies published between Jan 1, 1986, and May 6, 2022, that reported the prevalence of HPV DNA, or p16INK4a positivity, or both, in histologically verified vulvar cancer or vulvar intraepithelial neoplasia...
April 2023: Lancet Oncology
https://read.qxmd.com/read/36400098/5-year-outcomes-after-stereotactic-ablative-body-radiotherapy-for-primary-renal-cell-carcinoma-an-individual-patient-data-meta-analysis-from-irock-the-international-radiosurgery-consortium-of-the-kidney
#11
JOURNAL ARTICLE
Shankar Siva, Muhammad Ali, Rohann J M Correa, Alexander Muacevic, Lee Ponsky, Rodney J Ellis, Simon S Lo, Hiroshi Onishi, Anand Swaminath, Mark McLaughlin, Scott C Morgan, Fabio L Cury, Bin S Teh, Anand Mahadevan, Irving D Kaplan, William Chu, William Grubb, Raquibul Hannan, Michael Staehler, Andrew Warner, Alexander V Louie
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma, for which long-term data are awaited. The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma. METHODS: This study was an individual patient data meta-analysis, for which patients undergoing SABR for primary renal cell carcinoma across 12 institutions in five countries (Australia, Canada, Germany, Japan, and the USA) were eligible...
December 2022: Lancet Oncology
https://read.qxmd.com/read/36249794/identifying-optimal-pd-1-pd-l1-inhibitors-in-first-line-treatment-of-patients-with-advanced-squamous-non-small-cell-lung-cancer-in-china-updated-systematic-review-and-network-meta-analysis
#12
Mingye Zhao, Taihang Shao, Yinan Ren, Caicun Zhou, Wenxi Tang
Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq-NSCLC). Therefore, we aimed to indirectly compare the efficacy of these treatments to provide evidence for clinical decision and Chinese national reimbursement drug listing. Methods: We collected phase III clinical trials targeted on stage IIIB-IV patients for first-line immunotherapy of sq-NSCLC by systematically searching databases...
2022: Frontiers in Pharmacology
https://read.qxmd.com/read/36073967/crossover-in-adjuvant-trastuzumab-trials-sparing-toxicity-in-patient-care
#13
REVIEW
Jordan E Tuia, Timothée Olivier, Vinay K Prasad
OBJECTIVES: Design and reporting of randomized control trials for drug therapies in the adjuvant setting require a nuanced consideration of patient crossover. Adjuvant trials can be susceptible to the misuse of crossover and may distort the interpretation of findings. We sought to investigate and describe crossover and/or postprogression access to trastuzumab within adjuvant trastuzumab randomized control trials for human epidermal growth factor receptor 2-positive breast cancer patients...
October 1, 2022: American Journal of Clinical Oncology
https://read.qxmd.com/read/36058227/recurrence-free-survival-versus-overall-survival-as-a-primary-endpoint-for-studies-of-resected-colorectal-liver-metastasis-a-retrospective-study-and-meta-analysis
#14
JOURNAL ARTICLE
Brett L Ecker, Jasme Lee, Lily V Saadat, Thomas Aparicio, Florian E Buisman, Vinod P Balachandran, Jeffrey A Drebin, Kiyoshi Hasegawa, William R Jarnagin, Nancy E Kemeny, T Peter Kingham, Bas Groot Koerkamp, Norihiro Kokudo, Yutaka Matsuyama, Guillaume Portier, Leonard B Saltz, Kevin C Soares, Alice C Wei, Mithat Gonen, Michael I D'Angelica
BACKGROUND: Recurrence-free survival has been used as a surrogate endpoint for overall survival in trials involving patients with resected colorectal liver metastases. We aimed to assess the correlation between recurrence-free survival and overall survival after resection of colorectal liver metastases to determine the adequacy of this surrogate endpoint. METHODS: In this retrospective study and meta-analysis, we compiled an institutional cohort of consecutive patients who had complete resection of colorectal liver metastases from the Memorial Sloan Kettering Cancer Center (New York, NY, USA) prospective database...
October 2022: Lancet Oncology
https://read.qxmd.com/read/35835138/comparative-effectiveness-and-risk-of-preterm-birth-of-local-treatments-for-cervical-intraepithelial-neoplasia-and-stage-ia1-cervical-cancer-a-systematic-review-and-network-meta-analysis
#15
JOURNAL ARTICLE
Antonios Athanasiou, Areti Angeliki Veroniki, Orestis Efthimiou, Ilkka Kalliala, Huseyin Naci, Sarah Bowden, Maria Paraskevaidi, Marc Arbyn, Deirdre Lyons, Pierre Martin-Hirsch, Phillip Bennett, Evangelos Paraskevaidis, Georgia Salanti, Maria Kyrgiou
BACKGROUND: The trade-off between comparative effectiveness and reproductive morbidity of different treatment methods for cervical intraepithelial neoplasia (CIN) remains unclear. We aimed to determine the risks of treatment failure and preterm birth associated with various treatment techniques. METHODS: In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials database for randomised and non-randomised studies reporting on oncological or reproductive outcomes after CIN treatments from database inception until March 9, 2022, without language restrictions...
July 11, 2022: Lancet Oncology
https://read.qxmd.com/read/35709810/accuracy-and-effectiveness-of-hpv-mrna-testing-in-cervical-cancer-screening-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Marc Arbyn, Marie Simon, Silvia de Sanjosé, Megan A Clarke, Mario Poljak, Remila Rezhake, Johannes Berkhof, Victoria Nyaga, Murat Gultekin, Karen Canfell, Nicolas Wentzensen
BACKGROUND: Cervical cancer screening tests that identify DNA of the main causal agent, high-risk human papillomavirus (HPV) types, are more protective than cervical cytology. We systematically reviewed the literature to assess whether tests targeting high-risk HPV (hrHPV) mRNA are as accurate and effective as HPV DNA-based screening tests. METHODS: We did a systematic review to assess the cross-sectional clinical accuracy to detect cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) or 3 or worse (CIN3+) of hrHPV mRNA versus DNA testing in primary cervical cancer screening; the longitudinal clinical performance of cervical cancer screening using hrHPV mRNA versus DNA assays; and the clinical accuracy of hrHPV mRNA testing on self-collected versus clinician-collected samples...
June 13, 2022: Lancet Oncology
https://read.qxmd.com/read/35644163/stereotactic-radiosurgery-versus-whole-brain-radiotherapy-in-patients-with-intracranial-metastatic-disease-and-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#17
JOURNAL ARTICLE
Karolina Gaebe, Alyssa Y Li, Amy Park, Ambica Parmar, Benjamin H Lok, Arjun Sahgal, Kelvin K W Chan, Anders W Erickson, Sunit Das
BACKGROUND: Patients with small-cell lung cancer (SCLC) are at high risk for intracranial metastatic disease (IMD). Although stereotactic radiosurgery (SRS) has supplanted whole brain radiotherapy (WBRT) as first-line treatment for IMD in most solid cancers, WBRT remains first-line treatment for IMD in patients with SCLC. We aimed to evaluate the efficacy of SRS in comparison with WBRT and assess treatment outcomes following SRS. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, CENTRAL, and grey literature sources for controlled trials and cohort studies published in English reporting on SRS for IMD treatment in patients with SCLC from inception to March 23, 2022...
July 2022: Lancet Oncology
https://read.qxmd.com/read/35397210/risk-factors-and-prognostic-implications-of-diagnosis-of-cancer-within-30-days-after-an-emergency-hospital-admission-emergency-presentation-an-international-cancer-benchmarking-partnership-icbp-population-based-study
#18
JOURNAL ARTICLE
Sean McPhail, Ruth Swann, Shane A Johnson, Matthew E Barclay, Hazem Abd Elkader, Riaz Alvi, Andriana Barisic, Oliver Bucher, Gavin R C Clark, Nicola Creighton, Bolette Danckert, Cheryl A Denny, David W Donnelly, Jeff J Dowden, Norah Finn, Colin R Fox, Sharon Fung, Anna T Gavin, Elba Gomez Navas, Steven Habbous, Jihee Han, Dyfed W Huws, Christopher G C A Jackson, Henry Jensen, Bethany Kaposhi, S Eshwar Kumar, Alana L Little, Shuang Lu, Carol A McClure, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Sabuj Sarker, Luc Te Marvelde, Rebecca S Thomas, Robert J S Thomas, Catherine S Thomson, Ryan R Woods, Bin Zhang, Georgios Lyratzopoulos
BACKGROUND: Greater understanding of international cancer survival differences is needed. We aimed to identify predictors and consequences of cancer diagnosis through emergency presentation in different international jurisdictions in six high-income countries. METHODS: Using a federated analysis model, in this cross-sectional population-based study, we analysed cancer registration and linked hospital admissions data from 14 jurisdictions in six countries (Australia, Canada, Denmark, New Zealand, Norway, and the UK), including patients with primary diagnosis of invasive oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer during study periods from Jan 1, 2012, to Dec 31, 2017...
May 2022: Lancet Oncology
https://read.qxmd.com/read/35123662/aromatase-inhibitors-versus-tamoxifen-in-premenopausal-women-with-oestrogen-receptor-positive-early-stage-breast-cancer-treated-with-ovarian-suppression-a-patient-level-meta-analysis-of-7030-women-from-four-randomised-trials
#19
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineffective in premenopausal women when used without ovarian suppression. We aimed to investigate whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors. METHODS: We did a meta-analysis of individual patient data from randomised trials comparing aromatase inhibitors (anastrozole, exemestane, or letrozole) versus tamoxifen for 3 or 5 years in premenopausal women with ER-positive breast cancer receiving ovarian suppression (goserelin or triptorelin) or ablation...
March 2022: Lancet Oncology
https://read.qxmd.com/read/35051385/androgen-deprivation-therapy-use-and-duration-with-definitive-radiotherapy-for-localised-prostate-cancer-an-individual-patient-data-meta-analysis
#20
JOURNAL ARTICLE
Amar U Kishan, Yilun Sun, Holly Hartman, Thomas M Pisansky, Michel Bolla, Anouk Neven, Allison Steigler, James W Denham, Felix Y Feng, Almudena Zapatero, John G Armstrong, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Mary T Dunne, Jason A Efstathiou, Howard M Sandler, Araceli Guerrero, David Joseph, Philippe Maingon, Theo M de Reijke, Xavier Maldonado, Ting Martin Ma, Tahmineh Romero, Xiaoyan Wang, Matthew B Rettig, Robert E Reiter, Nicholas G Zaorsky, Michael L Steinberg, Nicholas G Nickols, Angela Y Jia, Jorge A Garcia, Daniel E Spratt
BACKGROUND: Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer. This individual patient data meta-analysis of relevant randomised trials aimed to quantify the benefit of these interventions in aggregate and in clinically relevant subgroups. METHODS: For this meta-analysis, we performed a systematic literature search in MEDLINE, Embase, trial registries, the Web of Science, Scopus, and conference proceedings to identify trials with results published in English between Jan 1, 1962, and Dec 30, 2020...
February 2022: Lancet Oncology
keyword
keyword
31053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.